TScan Therapeutics, Inc.
TCRX
$0.97
$0.1315.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -61.75% | 2.23% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.75% | 2.23% | |||
| Cost of Revenue | 18.79% | -41.81% | |||
| Gross Profit | -31.82% | 45.60% | |||
| SG&A Expenses | 37.27% | -23.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.32% | -38.26% | |||
| Operating Income | -33.31% | 41.01% | |||
| Income Before Tax | -24.76% | 35.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -24.76% | 35.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.76% | 35.66% | |||
| EBIT | -33.31% | 41.01% | |||
| EBITDA | -34.59% | 41.75% | |||
| EPS Basic | -169.64% | 71.89% | |||
| Normalized Basic EPS | -195.15% | 74.32% | |||
| EPS Diluted | -169.64% | 71.89% | |||
| Normalized Diluted EPS | -195.15% | 74.32% | |||
| Average Basic Shares Outstanding | -53.72% | 128.84% | |||
| Average Diluted Shares Outstanding | -53.72% | 128.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||